EBS - Emergent gets research award from US DoD for chikungunya vaccine study

• Emergent BioSolutions (EBS) said it received a research award from the U.S. Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) to evaluate its single-dose chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate.
• Emergent said it will start the planning phase, the first of two phases, in collaboration with the Armed Forces Research Institute of Medical Sciences (AFRIMS) and academic partners, to enable a post-approval field efficacy study in areas with active chikungunya virus (CHIKV) transmission.
• The total program budget is ~$10M for the planning and clinical study phases.
• The post-approval, phase 3b trial will evaluate the vaccine's efficacy in preventing CHIKV disease and test the utility of a model-guided disease surveillance framework to optimize execution of a field efficacy trial using CHIKV as a model emerging pathogen, the company added.
• Chikungunya virus is spread to people by infected mosquitoes.

For further details see: